Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite?s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite?s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
A live Q&A session, open to current and prospective investors, will immediately follow CEO Dr. Pnina Fishman's presentation.
For more information on Can-Fite BioPharma (NYSE American: CANF), visit http://www.canfinfo.com/
View investor deck